JAK3 and rheumatoid arthritis: Tofacitinib (TOF) inhibits JAK1/JAK3 and has been proven effective in rheumatoid arthritis (RA), psoriatic arthritis, ulcerative colitis, and a new therapeutic option in systemic lupus [8].